According to MRFR, the Digital Pathology Market is expected to register a CAGR of 6.5% over the review period from 2021 to 2028 and expected to reach USD 1.4 Billion by 2028. Factors poised to drive digital pathology market demand during the assessment period are the increase in the number of pathologists, the benefits of digital pathology, and its rapid use in the healthcare sector.
A massive number of patients visiting health facilities on a daily basis has resulted from the current COVID-19 pandemic. The number of pathological tests conducted globally has diminished because of the COVID-19 outbreak. Furthermore, the globally implemented lockdowns and restrictions have negatively affected the demand for these solutions in 2020. However during the forecast period, the FDA approval for the use of digital pathology solutions for primary diagnostic purposes is expected to increase demand. The need for better remote access to evaluate the diagnostic tests of patients is therefore expected to increase the demand for digital pathology solutions in the next five years.
Major factors likely to influence the purchasing decisions of hospitals and clinics are electronic health records (EHRs) adoption, automation integration to expedite workflow, and technological improvements in software for image analysis. Speedy technological advances in the digital pathology system, such as advances in digital imaging, robotic light microscopy, and various fibre optic communications, among others, will be the main drivers of digital pathology market. Laboratory efficiency improvements are critical because patients and doctors rely on laboratory outcomes for diagnostic decisions, and diagnostic tests need to be completed and reported quickly and accurately. In addition, the increasing prevalence of chronic conditions is expected to increase the demand for digital pathology to improve existing patient diagnostic imaging measures and reduce the high costs associated with traditional diagnostic methods.
For players operating in the digital pathology market, the development of affordable scanners is expected to offer growth opportunities. Most private medical practises are small businesses and are unable to afford costly systems of digital pathology. The introduction of affordable scanners among pathologists with low or limited budgets will encourage their adoption.
However a significant cost is incurred by the paradigmatic shift these machines offer in healthcare. It is quite costly to implement as it includes several related technologies such as scanners, computer servers, pathologists' workstations, and medical displays. During the forecast period, this may significantly reduce the prospective growth rate. In addition, digital pathology's high implementation costs combined with strict regulatory policies can act as roadblocks for the digital pathology market.
Growing Research Toward Human Pathology to Drive the Market Growth
Human pathology and animal pathology are included in the type-based segmentation of the digital pathology market, where the former has a significant hold of almost 65 percent of the market. In evaluating the development of this sub-segment, the prevalence of chronic diseases can be considered.
Hardware, software and storage comprise the product-wise segmentation of the market. In delivering the results of these tests, the hardware segment plays a pivotal role and ensures the maximum digital pathology market share.
Growing demand for Early Diagnosis drives Digital Detection Segment
The digital pathology industry has divisions such as disease detection, MH, drug discovery, and telemedicine, depending on use. The digital pathology market lead is provided by the introduction of technologies in disease detection, and the segment will hit a significant value of by the end of the review period.
Growing Investments Drive the Growth of Research Centres & Academic Institutes Segment
The digital pathology market includes hospitals & clinics, diagnostic centres, and research centres & academic institutes on the basis of end users. This technology is gaining substantial demand from research centres & academic institutes as it empowers them with faster and more accurate information that helps to analyse different diseases in detail.
The digital pathology market regional research includes developments in regions such as the Americas, Asia Pacific (APAC), Europe, and the Middle East & Africa (MEA).
The prevalence of chronic illnesses, growing healthcare spending, and the propensity to embrace the new technology give the Americas unparalleled influence over other regions. As the industry leader, this has pushed the Americas. The area is also heavily engaged in pathological research that are moving the digital pathology market forward.
The maintenance of the second European position depends exclusively on the participation of a number of main players in the field, such as Leica Biosystems, Definiens, and others. Often an aspect that should not be overlooked is the progressive proliferation of chronic diseases.
Among the rising areas, APAC is anticipated to be the fastest. A CAGR of almost 13.53 percent will guarantee the prospect of this demand in the region during the forecast period. For the regional digital pathology industry, the ever-growing healthcare spending of countries such as China and India holds considerable promise. Medical tourism can contribute significantly to the market in Thailand, Singapore, and India.
As the area doesn't spend much on healthcare, the MEA might not be able to report substantial growth. However in the future, growing health-related consciousness will fuel the sector.
The digital pathology industry is distinguished by a variety of well-established and small players, while the global digital pathology market continues to be highly competitive and decentralised. In developing markets, global players are increasingly expanding their presence, placing pressure on regional players, especially in terms of features such as form, product portfolios, and pricing. The industry is seeing increased competition, which during the projected timeframe is expected to further escalate. In order to achieve strategic edge in this industry and to retain their digital pathology market share, well-established players enter into mergers & acquisitions, alliance, cooperation, growth and product launch.
December 2020: Charles River Laboratories International, Inc. announced their partnership Deciphex Patholytix Preclinical for toxicologic pathology. Charles River will optimize Patholytix Preclinical tools through its collaboration with Deciphex, a pioneer in preclinical digital pathology software-as-a-service, to use this industry-leading, validated digital peer review process to streamline and expedite the process of ensuring the consistency and integrity of studies.
December 2020: US-based digital pathology startup Proscia acquired USD 23 million to advance software platform, Concentriq, fundamentally an operating system for digital scanners used in the evaluation of tissue biopsies.
This report focuses on the growth of the global epilepsy therapeutics market and consists of an extensive executive summary, including a market snapshot that includes details about different segments of the market. It also offers an overview of market competitiveness in terms of geography and market share analysis by leading participants, providing a detailed analysis of the overall competitive situation emerging in the epilepsy therapeutic market. The study also offers knowledge and data analyses of the global market for its commodity, distribution channel, and regional segments.
|Market Size||USD 1.4 Billion|
|Forecast Units||Value (USD Billion)|
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, and Trends|
|Segments Covered||Type, Product, Application and End-user|
|Geographies Covered||North America, Europe, Asia-Pacific, and Rest of the World (RoW)|
|Key Vendors||Olympus Corporation (Japan), Danaher Corporation (Leica Biosystems GmbH) (U.S.), Inspirata (U.S.), 3DHISTECH Ltd. (Hungary), Huron Digital Pathology Inc. (Canada), Koninklijke Philips N.V. (The Netherlands), Hoffmann-La Roche Ltd. (Switzerland), microdimensions GmbH (Germany), Definiens (Germany), Mikroscan Technologies, Inc. (U.S.)|
|Key Market Opportunities||The development of affordable scanners is expected to offer growth opportunities|
|Key Market Drivers||
The global market of digital pathologyis expected to balloon to USD 1.4 Billion by 2028.
Huron Digital Pathology Inc., Danaher Corporation (Leica Biosystems GmbH), Koninklijke Philips N.V., microdimensions GmbH, Definiens, 3DHISTECH Ltd., F. Hoffmann-La Roche Ltd., Mikroscan Technologies, Inc., Olympus Corporation, and Inspirata are major players of the global market of digital pathology.
Rising number of pathologists, awareness of the benefits of pathology, and the rapid implementation in the healthcare sector are major drivers of the global market.
High implementation costs of digital pathology pose a great challenge to the market.
The Americas can dominate the global market of digital pathology due to a tendency of adopting the latest technology and prevalence of chronic diseases.
APAC can exhibit a CAGR of 6% from 2018 to 2028 in the global market of digital pathology.
The global market of digital pathology is expected to exhibit a CAGR of 6.5% from 2021 to 2028.
The global digital pathology market is characterized by the presence of many global, regional, and local vendors. The market is highly competitive with all the players competing to gain the market share. Intense competition, rapid advances in technology, frequent changes in government policies, and environmental regulations are key factors that confront the market growth. The vendors compete based on cost, quality, and reliability. It is decisive for the vendors to provide cost-efficient and high-quality products, to survive and succeed in an intensely competitive market environment. Some of the well-established companies in this market are Koninklijke Philips N.V., Danaher Corporation (Leica Biosystems GmbH), Definiens, F. Hoffmann-La Roche Ltd, and microdimensions GmbH. These companies continue to retain their strong market presence through expansions, mergers and acquisitions, collaborations, and extensive product launches.
Koninklijke Philips N.V., a Dutch multinational technology company is headquartered in Amsterdam and has three main divisions, namely, Philips Healthcare, Philips Consumer Lifestyle, and Signify N.V. The company aims to improve people’s lives globally through meaningful innovation. The company’s health care business makes up 42% of its total global sales revenue. In March 2017, the company announced that it is developing Philips IntelliSite Collaboration Suite that allows pathologists to connect worldwide and the Philips IntelliSite Pathology Solution which enables the support of additional image file formats to its image management system. In June 2016, the company acquired PathXLa Belfast-based digital imaging analysis and software company, thereby expanding its digital pathology solutions.
Danaher Corporation (Leica Biosystems GmbH) specializes in the production and commercialization of microscopes and scientific instruments for the analysis of microstructures and nanostructures. The company is headquartered in Germany and has its distribution network in more than 100 countries. In September 2017, Leica Biosystems announced that it has delivered and installed around 2,000 digital pathology scanners. Furthermore, in May 2016, the company announced its collaboration with the UCLA Department of Pathology and Laboratory Medicine to accelerate innovation and adoption of digital pathology.
Inspirata acquired the third largest spot in the global digital pathology market. The company focuses on advancing pathology solutions by leveraging the latest tools and technologies to accelerate cancer detection, diagnosis, and treatment. In January 2018, the company acquired Omnyx from GE Healthcare, thus, enhancing its digital pathology workflow solution.
Hoffmann-La Roche Ltd, a Swiss multinational healthcare company is located in Switzerland and has two operating segments, namely, pharmaceuticals and diagnostics. The company seeks to deliver clinically sound, accurate, and advanced medical insights to patients. In March 2018, the company announced the launch of VENTANA DP 200 high-speed slide scanner, which reduces workflow errors and provides excellent image quality and reliability. In January 2018, Roche and GE entered into a partnership to develop the integrated digital diagnostics platform for improving oncology and critical care treatment.
The growth of digital pathology market vendors is dependent on market conditions, government support, and industry development. Thus, the companies are focusing on expanding geographically, on collaborations, product launches, mergers and acquisitions, and improving their products.